The London Clinic, a leading private hospital in the United Kingdom, has performed nearly 100 Nociscan procedures, reflecting growing clinical adoption of the diagnostic technology for chronic low back pain evaluation. Aclarion, Inc., the commercial-stage healthcare technology company behind Nociscan, released a video featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon and Lead Clinician at The London Spine Clinic, discussing his experience with the technology in clinical practice.
Mr. Sutcliffe, who has over 30 years of experience treating spinal conditions and frequently handles complex referrals, stated that Nociscan provides an additional layer of insight that complements traditional imaging. "Having more objective data can help inform clinical decisions and improve confidence when evaluating patients with chronic low back pain," he explained in the video available at https://www.aclarion.com/nociscan-video. The sustained use at The London Clinic indicates increasing integration into routine clinical workflows.
Nociscan represents a significant advancement in addressing chronic low back pain, a global healthcare challenge affecting approximately 266 million people worldwide. The non-invasive solution uses magnetic resonance spectroscopy (MRS) and proprietary signal processing to identify chemical biomarkers associated with disc pain in the lumbar spine. This helps physicians differentiate between painful and non-painful discs, providing critical information for treatment planning.
Clinical data demonstrates that when used alongside other diagnostic tools, Nociscan has contributed to surgical success rates of up to 97% when all Nociscan-positive discs are treated. This precision in identifying pain sources could potentially reduce unnecessary procedures and improve patient outcomes. Brent Ness, Chief Executive Officer of Aclarion, noted that approaching 100 scans at an international center like The London Clinic serves as an important indicator of increasing adoption and reinforces Nociscan's potential as a valuable clinical tool.
The technology's growing acceptance at prestigious medical institutions suggests a shift toward more objective, biomarker-driven approaches in spine care. For patients suffering from chronic low back pain, this could mean more accurate diagnoses and targeted treatments. The continued utilization at The London Clinic, where Mr. Sutcliffe and his colleagues have incorporated Nociscan into their assessment protocols, demonstrates real-world physician engagement with the technology. More information about Aclarion and its technology platform can be found at https://www.aclarion.com.
